血清miR-499与急性冠脉综合征患者冠状动脉病变严重程度的相关性分析

doi:10.3969/j.issn.1674-8115.2024.04.007

摘要/Abstract

摘要：

目的·探讨急性冠脉综合征（acute coronary syndrome，ACS）患者血清中miR-499表达水平对冠状动脉病变严重程度的预测价值。方法·纳入就诊于上海交通大学医学院附属新华医院的ACS患者74例，根据Gensini评分将患者分为轻度组（30例）、中度组（21例）及重度组（23例）。荧光实时定量聚合酶链反应（real-time quantitative polymerase chain reaction，qPCR）技术检测血清miR-499的表达量，同时检测肌钙蛋白（cTnI）、肌酸激酶同工酶（CK-MB）、肌红蛋白（Mb）、脑钠肽（BNP）、左心室射血分数（LVEF）等实验室指标。采用Spearman相关分析评估miR-499表达水平与Gensini 评分、冠状动脉病变血管支数的相关性。受试者操作特征（receiver operating characteristic，ROC）曲线分析miR-499对冠状动脉病变严重程度的评估价值。结果·miR-499的表达水平随着冠状动脉病变程度的加重呈上升趋势，组间差异有统计学意义（P=0.000）。miR-499表达水平与Gensini 评分、cTnI水平呈正相关（r值分别为0.331、0.143，P<0.05），与LVEF无相关性（P>0.05）；Gensini评分与cTnI、LVEF均无相关性（P>0.05）。ROC曲线分析结果显示，miR-499评估冠状动脉病变严重程度的AUC为0.802（95%CI 0.698~0.906），灵敏度为65.2%，特异度为80.4%。miR-499表达水平随着冠状动脉病变支数的增多呈升高趋势，且与冠状动脉病变支数呈正相关（r=0.368，P<0.05）。结论·ACS患者血清中miR-499表达水平与冠状动脉病变严重程度及病变支数相关，对冠状动脉病变严重程度具有一定评估价值。

关键词: miR-499, 急性冠脉综合征, 生物标志物, 冠状动脉狭窄

Abstract:

Objective ·To explore the value of miR-499 expression levels in the serum of patients with acute coronary syndrome (ACS) in predicting the severity of coronary artery disease. Methods ·Seventy-four patients with ACS admitted to Xinhua Hospital, Shanghai Jiao Tong University School of Medicine were included and divided into a mild group of 30 cases, a moderate group of 21 cases, and a severe group of 23 cases according to the Gensini score. Real-time quantitative polymerase chain reaction (qPCR) technology was used to detect the expression level of serum miR-499, while troponin (cTnI), creatine kinase isoenzyme (CK-MB), myoglobin (Mb), brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), and other laboratory indicators were measured. Spearman correlation analysis was used to analyze the correlation between the expression level of miR-499 and Gensini score, as well as the number of vessel branches in coronary artery disease. The evaluation value of miR-499 in assessing the severity of coronary artery disease was analyzed by using receiver operating characteristic (ROC) curve. Results ·The expression level of miR-499 increased with the severity of coronary artery disease (P=0.000). The expression level of miR-499 was positively correlated with Gensini score and cTnI (r=0.331, r=0.143, P<0.05), respectively, but not with LVEF (P>0.05), while Gensini score was not correlated with cTnI and LVEF (P>0.05). ROC analysis showed that the AUC of miR-499 for assessing the severity of coronary artery disease was 0.802 (95% CI 0.698?0.906), with sensitivity of 65.2% and specificity of 80.4%. The expression level of miR-499 increased with the increase of the number of coronary artery lesions, and was positively correlated with the number of coronary artery lesions (r=0.368, P<0.05). Conclusion ·The expression level of miR-499 in the serum of ACS patients is correlated with the severity and number of coronary artery lesions, which has a certain evaluation value in evaluating the severity of coronary artery lesions.

Key words: miR-499, acute coronary syndrome, biomarker, coronary artery stenosis

中图分类号:

R543.3

唐冬娟, 江来, 江叶. 血清miR-499与急性冠脉综合征患者冠状动脉病变严重程度的相关性分析[J]. 上海交通大学学报（医学版）, 2024, 44(4): 469-473.

TANG Dongjuan, JIANG Lai, JIANG Ye. Correlation analysis of serum miR-499 and severity of coronary lesions in patients with acute coronary syndrome[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 469-473.

图/表 3

参考文献 20

1	WADA H, MIYAUCHI K, DAIDA H. Gender differences in the clinical features and outcomes of patients with coronary artery disease[J]. Expert Rev Cardiovasc Ther, 2019, 17(2): 127-133.
2	TONG K L, MAHMOOD ZUHDI A S, WAN AHMAD W A, et al. Circulating microRNAs in young patients with acute coronary syndrome[J]. Int J Mol Sci, 2018, 19(5): E1467.
3	GRÜNTZIG A R, SENNING A, SIEGENTHALER W E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty[J]. N Engl J Med, 1979, 301(2): 61-68.
4	GOELLER M, ACHENBACH S, CADET S, et al. Pericoronary adipose tissue computed tomography attenuation and high-risk plaque characteristics in acute coronary syndrome compared with stable coronary artery disease[J]. JAMA Cardiol, 2018, 3(9): 858-863.
5	WANG G K, ZHU J Q, ZHANG J T, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans[J]. Eur Heart J, 2010, 31(6): 659-666.
6	LIU X, FAN Z, ZHAO T, et al. Plasma miR-1, miR-208, miR-499 as potential predictive biomarkers for acute myocardial infarction: an independent study of Han population[J]. Exp Gerontol, 2015, 72: 230-238.
7	CORSTEN M F, DENNERT R, JOCHEMS S, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease[J]. Circ Cardiovasc Genet, 2010, 3(6): 499-506.
8	LI H Y, ZHAO X, LIU Y Z, et al. Plasma microRNA-126-5p is associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris[J]. Cell Physiol Biochem, 2016, 39(3): 837-846.
9	LI H, GAO F, WANG X, et al. Circulating microRNA-378 levels serve as a novel biomarker for assessing the severity of coronary stenosis in patients with coronary artery disease[J]. Biosci Rep, 2019, 39(5): BSR20182016.
10	ZHU G F, YANG L X, GUO R W, et al. MicroRNA-155 is inversely associated with severity of coronary stenotic lesions calculated by the Gensini score[J]. Coron Artery Dis, 2014, 25(4): 304-310.
11	中国医师协会急诊医师分会.2015中国急诊急性冠脉综合症临床实践指南(二): 诊断篇[J]. 中国急救医学, 2016, 36(1): 9-11.
	Emergency Physician Branch of Chinese Medical Doctor Association. 2015 China emergency acute coronary syndrome clinical practice guidelines (Ⅱ): diagnosis section[J].Chinese Journal of Critical Care Medicine, 2016, 36(1): 9-11.
12	CHENG J, CHENG A, CLIFFORD B L, et al. MicroRNA-144 silencing protects against atherosclerosis in male, but not female mice[J]. Arterioscler Thromb Vasc Biol, 2020, 40(2): 412-425.
13	ARDERIU G, PEÑA E, ALEDO R, et al. MicroRNA-145 regulates the differentiation of adipose stem cells toward microvascular endothelial cells and promotes angiogenesis[J]. Circ Res, 2019, 125(1): 74-89.
14	HE W, ZHU L, HUANG Y, et al. The relationship of microRNA-21 and plaque stability in acute coronary syndrome[J]. Medicine (Baltimore), 2019, 98(47): e18049.
15	WANG J, JIA Z, ZHANG C, et al. MiR-499 protects cardiomyocytes from H₂O₂-induced apoptosis via its effects on Pdcd4 and Pacs2[J]. RNA Biol, 2014, 11(4): 339-350.
16	REN J, ZHANG J, XU N, et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease[J]. PLoS One, 2013, 8(12): e80738.
17	ROMAINE S P, TOMASZEWSKI M, CONDORELLI G, et al. MicroRNAs in cardiovascular disease: an introduction for clinicians[J]. Heart, 2015, 101(12): 921-928.
18	AI J, ZHANG R, LI Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction[J]. Biochem Biophys Res Commun, 2010, 391(1): 73-77.
19	DEVAUX Y, VAUSORT M, GORETTI E, et al. Use of circulating microRNAs to diagnose acute myocardial infarction[J]. Clin Chem, 2012, 58(3): 559-567.
20	NEELAND I J, PATEL R S, ESHTEHARDI P, et al. Coronary angiographic scoring systems: an evaluation of their equivalence and validity[J]. Am Heart J, 2012, 164(4): 547-552.e1.

Item	Mild group (n=30)	Moderate group (n=21)	Severe group (n=23)	P value
Age/year	64.6±12.2	63.1±12.2	63.9±8.5	0.903
Gender/(male/female)/n	21/9	19/2	19/4	0.191
Diabetes/n(%)	6 (20.0)	8 (38.1)	8 (34.8)	0.319
CHD/n(%)	6 (20.0)	5 (23.8)	3 (13.0)	0.658
Smoking/n(%)	16 (53.3)	11 (52.4)	12 (52.2)	0.996
Hypertension/n(%)	19 (63.3)	13 (61.9)	13 (56.5)	0.879
HDL-C/(mmol·L^-1)	1.22±0.26	1.19±0.27	1.22±0.21	0.867
LDL-C/(mmol·L^-1)	2.70±0.88	2.56±0.66	2.91±0.97	0.414
Mb/(ng·mL^-1)	43.00 (19.38‒234.45)	52.80 (24.65‒123.85)	113.20 (51.20‒259.50)	0.392
CK-MB/(ng·mL^-1)	2.95 (1.45‒42.25)	3.30 (2.10‒7.30)	4.40 (2.50‒21.30)	0.528
cTnI/(ng·mL^-1)	0.15 (0.02‒1.57)	0.12 (0.03‒0.20)	0.15 (0.05‒0.74)	0.660
LVEF/%	56.26±7.03	57.97±7.51	58.43±6.22	0.795
miR-499	3.36±1.99	4.81±1.66	6.79±2.34	0.000

Item	Mild group (n=30)	Moderate group (n=21)	Severe group (n=23)	P value
Age/year	64.6±12.2	63.1±12.2	63.9±8.5	0.903
Gender/(male/female)/n	21/9	19/2	19/4	0.191
Diabetes/n(%)	6 (20.0)	8 (38.1)	8 (34.8)	0.319
CHD/n(%)	6 (20.0)	5 (23.8)	3 (13.0)	0.658
Smoking/n(%)	16 (53.3)	11 (52.4)	12 (52.2)	0.996
Hypertension/n(%)	19 (63.3)	13 (61.9)	13 (56.5)	0.879
HDL-C/(mmol·L^-1)	1.22±0.26	1.19±0.27	1.22±0.21	0.867
LDL-C/(mmol·L^-1)	2.70±0.88	2.56±0.66	2.91±0.97	0.414
Mb/(ng·mL^-1)	43.00 (19.38‒234.45)	52.80 (24.65‒123.85)	113.20 (51.20‒259.50)	0.392
CK-MB/(ng·mL^-1)	2.95 (1.45‒42.25)	3.30 (2.10‒7.30)	4.40 (2.50‒21.30)	0.528
cTnI/(ng·mL^-1)	0.15 (0.02‒1.57)	0.12 (0.03‒0.20)	0.15 (0.05‒0.74)	0.660
LVEF/%	56.26±7.03	57.97±7.51	58.43±6.22	0.795
miR-499	3.36±1.99	4.81±1.66	6.79±2.34	0.000

[1]	冯佳丽, 彭宇, 段君凯. 川崎病相关微RNA的功能机制及生物标志物研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(2): 256-260.
[2]	张锰, 崔青, 朱荻绮, 张玉奇, 钟玉敏, 沈捷. 川崎病合并冠状动脉病变患儿21例冠状动脉造影复查分析[J]. 上海交通大学学报（医学版）, 2023, 43(12): 1535-1541.
[3]	蒋文群, 侯品品, 陈燕, 贾锋, 张晓华, 高丽, 胡琴. 急性缺血性脑卒中患者血清肾胺酶表达特征及临床意义[J]. 上海交通大学学报（医学版）, 2023, 43(1): 29-35.
[4]	张梦吉, 黄琳, 李峥, 马卓然, 魏霖, 袁安彩, 胡刘华, 张薇, 钱昆, 卜军. 基于人群大队列探索心脑血管疾病相关血浆代谢组学特征[J]. 上海交通大学学报（医学版）, 2022, 42(3): 259-266.
[5]	陈仪婷, 赵安达, 李荣, 康文慧, 李生慧. 循环外泌体微RNA在支气管哮喘中的作用综述[J]. 上海交通大学学报（医学版）, 2022, 42(3): 375-380.
[6]	熊雷, 易茜, 许明芳, 陈健. MRPL12在肺腺癌中的表达和预后分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1033-1040.
[7]	凌徐心仪, 张瑶, 钟华. 非小细胞肺癌免疫治疗获益人群筛选的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(8): 1114-1119.
[8]	王昱欢, 丁奕岑, 蔡瑶雨, 康亚妮. 差异表达微RNA作为多囊卵巢综合征生物标志物的研究[J]. 上海交通大学学报(医学版), 2021, 41(11): 1429-1435.
[9]	朱琳，刘军. 多系统萎缩生物标志物的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(9): 1302-1307.
[10]	王晓霞1，许天祥2，吕镗烽3，胥武剑3，刘建波1，宋勇3. 急性呼吸窘迫综合征患者香叶基香叶基焦磷酸合成酶的表达及其临床意义[J]. 上海交通大学学报(医学版), 2020, 40(5): 639-645.
[11]	唐冬娟，薛晓梅，何斌. miR-133a对急性心肌梗死的早期诊断及预后评估价值[J]. 上海交通大学学报（医学版）, 2020, 40(3): 339-.
[12]	张伟然1, 2，林雪峰3，李鑫2，张浩2，王猛2，孙伟2，韩兴鹏2，孙大强1, 4. 转录组分析鉴定肺腺癌潜在的生物标志物[J]. 上海交通大学学报(医学版), 2020, 40(12): 1598-1606.
[13]	况俊良，郑晓皎，赵爱华，贾伟. 代谢性疾病中胆汁酸水平变化及相关治疗策略[J]. 上海交通大学学报（医学版）, 2019, 39(6): 678-.
[14]	陶逸菁 1，夏智丽 1，高程洁 2，高亚洁 1，吴昊 3，万青 1，李永光 1，陆志刚 1，沈成兴 1，潘静薇 1. 急性心肌梗死再血管化成功后预测左心室重构相关生物标志物的分析[J]. 上海交通大学学报（医学版）, 2019, 39(1): 60-.
[15]	曹惠敏，尤纱纱，薛雨晨，何斌. 血清 miR-499 和 miR-652用于急性冠脉综合征早期诊断的临床试验#br#[J]. 上海交通大学学报（医学版）, 2017, 37(9): 1226-.